Dato-DXd治疗晚期非小细胞肺癌新进展  

New Advances in Dato-DXd Treatment for Advanced Non-Small-Cell Lung Cancer

作　　者：陈露露 宋启斌[1] CHEN Luu;SONG Qibin(Cancer Center,Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院肿瘤中心,武汉430060

出　　处：《肿瘤防治研究》2024年第7期535-541,共7页Cancer Research on Prevention and Treatment

基　　金：国家自然科学基金(82102841,82273094)。

摘　　要：约50%的非小细胞肺癌(NSCLC)患者在确诊时已处于晚期,尽管目前的标准治疗已将靶向治疗、免疫治疗和全身化疗纳入其中,但患者的预后仍然充满挑战。研究发现,人滋养层细胞表面抗原2(TROP2)在NSCLC中广泛表达,并与患者不良预后密切相关。本文深入探讨了针对TROP2的新型抗体偶联药物datopotamab deruxtecan(Dato-DXd,DS-1062)在NSCLC治疗中的最新应用进展,详细分析了Dato-DXd的技术设计,通过最新的临床试验数据评估了其疗效及安全性。Approximately 50%of patients with non-small-cell lung cancer(NSCLC)are diagnosed at advanced stages and face a challenging prognosis despite the integration of targeted therapies,immun-otherapy,and systemic chemotherapy into current standard care.A key factor in this context is trophoblast cell-surface antigen 2(TROP2),which is widely expressed in NSCLC and strongly associated with poor patient outcomes.This article examines the latest developments in the application of datopotamab deruxtecan(Dato-DXd,DS-1062),a novel antibody-drug conjugate targeting TROP2,in the treatment of NSCLC.It provides a detailed assessment of Dato-DXd’s technical design,evaluates its efficacy by using recent clinical trial data,and discusses its safety profile.

关 键 词：非小细胞肺癌 抗体偶联药物 人滋养层细胞表面抗原2 Dato-DXd 

分 类 号：R734.2[医药卫生—肿瘤]